Is it appropriate to prescribe gabapentin 300 mg twice daily with an additional 300 mg as needed for anxiety in an adult patient?

Gabapentin for Anxiety: Not Recommended as Prescribed

The proposed regimen of gabapentin 300 mg twice daily plus 300 mg as needed for anxiety is not supported by evidence-based guidelines and should not be prescribed. Gabapentin lacks FDA approval for anxiety disorders, has no established evidence-based dosing for this indication, and the "as needed" component is particularly problematic given concerns about tolerance, dependence, and misuse 1.

Why This Regimen Is Inappropriate

Lack of Guideline Support

• No major psychiatric guidelines recommend gabapentin as first-line or even second-line treatment for anxiety disorders 2.
• The Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology guidelines (2023) recommend SSRIs and SNRIs (venlafaxine) for social anxiety disorder, with cognitive behavioral therapy as the preferred psychotherapy—gabapentin is not mentioned 2.
• A comprehensive 2022 systematic review concluded there is minimal evidence for gabapentin in anxiety disorders and it should only be used "with strong justification" 3.

FDA Labeling Does Not Support This Use

• Gabapentin is FDA-approved only for postherpetic neuralgia and partial onset seizures—not anxiety 1.
• The FDA label specifies structured dosing schedules (typically 300 mg three times daily, titrated up to 1800-3600 mg/day for approved indications), not "as needed" dosing 1.
• The maximum time between doses should not exceed 12 hours for approved indications, which contradicts an "as needed" approach 1.

Evidence Quality Is Poor

• Most studies of gabapentin for anxiety are small, short-term, and show only marginal benefits 4, 5, 6, 7.
• A 2000 placebo-controlled trial in panic disorder showed no overall drug/placebo difference in the primary outcome; benefits were only seen in post-hoc analysis of severely ill patients 5.
• A 2012 breast cancer survivor study found anxiolytic effects at both 300 mg and 900 mg daily, but this was a highly specific population with cancer-related anxiety, not generalized anxiety disorder 4.
• A 2019 comprehensive review concluded that evidence does not support gabapentin use for major depressive disorder, PTSD, OCD, or generalized anxiety disorder 8.

Safety Concerns

Risk of Dependence and Misuse

• Gabapentin was reclassified as a Schedule V controlled substance due to risks of tolerance, dependence, addiction, and withdrawal 9.
• Between 2011-2016,58.4% of off-label gabapentin visits involved concomitant CNS depressants (opioids, benzodiazepines, antidepressants), significantly increasing safety risks 10.
• Deaths involving pregabalin (a related gabapentinoid) now exceed those from diazepam, fentanyl, tricyclics, or SSRIs as groups, with rates rising steeply over the past decade 9.

"As Needed" Dosing Is Problematic

• There is no evidence base for PRN gabapentin dosing in anxiety 1.
• Gabapentin requires consistent dosing for therapeutic effect due to its pharmacokinetics and mechanism of action (binding to voltage-gated calcium channels) 2.
• PRN use may promote misuse patterns and does not align with how the medication achieves anxiolytic effects 9.

What Should Be Prescribed Instead

First-Line Evidence-Based Options

• SSRIs (sertraline, paroxetine, escitalopram) or SNRIs (venlafaxine) are the recommended first-line pharmacological treatments for anxiety disorders 2.
• Cognitive behavioral therapy specifically designed for anxiety disorders is strongly recommended and may be superior to pharmacotherapy alone 2.

If SSRIs/SNRIs Are Contraindicated or Ineffective

• Buspirone (5 mg twice daily, titrated to 20 mg three times daily) is a non-addictive anxiolytic option 2.
• Short-term benzodiazepines (lorazepam, oxazepam) may be appropriate for acute anxiety with careful monitoring, though they carry dependence risks 2.
• Tricyclic antidepressants (nortriptyline 10 mg at bedtime, titrated to 40 mg/day) have evidence for anxiety but require cardiac monitoring 2.

When Gabapentin Might Be Considered (Rarely)

If a patient has failed multiple evidence-based treatments and has severe, treatment-refractory anxiety:

• Use structured dosing only: Start 300 mg once daily, increase by 300 mg every 3-7 days as tolerated, targeting 900-1800 mg/day in divided doses (three times daily) 2.
• Never prescribe "as needed" dosing 1.
• Document the rationale extensively, including failed trials of SSRIs, SNRIs, and psychotherapy 8.
• Monitor closely for misuse, especially in patients with substance use history or concurrent opioid/benzodiazepine use 10, 9.
• Reassess risk-benefit at 6 months before continuing 2.

Common Pitfalls to Avoid

• Do not use gabapentin as a first-line anxiolytic simply because it is "non-addictive" compared to benzodiazepines—this perception is outdated given current evidence on gabapentinoid risks 9.
• Do not prescribe PRN gabapentin for anxiety—there is no evidence for this approach and it may promote problematic use patterns 1.
• Do not assume gabapentin is safer than benzodiazepines—both carry significant risks of dependence, and gabapentinoid-related deaths are rising 9.
• Do not overlook renal function—gabapentin requires dose adjustment in renal impairment, which is common in older adults 1.